(-0.08%) 5 464.87 points
(0.10%) 39 151 points
(0.11%) 17 737 points
(-0.02%) $80.81
(-5.04%) $2.62
(-0.84%) $2 311.30
(-0.22%) $28.81
(3.19%) $1 017.90
(0.35%) $0.936
(0.75%) $10.68
(0.53%) $0.792
(-0.30%) $87.23
-0.34% $ 5.81
Live Chart Being Loaded With Signals
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States...
Stats | |
---|---|
Volumen de hoy | 64 126 |
Volumen promedio | 229 541 |
Capitalización de mercado | 200.47M |
EPS | $-0.400 ( Q3 | 2023-11-07 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.38 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.270 (4.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-10 | Mcfarlane Neil F. | Buy | 600 000 | Stock Option (right to buy) |
2023-10-10 | Mcfarlane Neil F. | Buy | 200 000 | Restricted Stock Unit |
2023-10-10 | Mcfarlane Neil F. | Buy | 0 | |
2023-09-05 | Schafer Joshua | Buy | 500 | Common Stock |
2023-09-06 | Clifton R. Laduane | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
97.24 |
Last 89 transactions |
Buy: 4 356 177 | Sell: 72 592 |
Volumen Correlación
KemPharm Inc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
KemPharm Inc Correlación - Moneda/Commodity
KemPharm Inc Finanzas
Annual | 2022 |
Ingresos: | $10.46M |
Beneficio Bruto: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2022 |
Ingresos: | $10.46M |
Beneficio Bruto: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2021 |
Ingresos: | $28.65M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.15 |
FY | 2020 |
Ingresos: | $13.29M |
Beneficio Bruto: | $11.98M (90.18 %) |
EPS: | $-3.21 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
KemPharm Inc
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico